European Industry Leaders From Energy, Mobility & Sustainability Join Energy Impact Partners Global Innovation Platform
16.7.2020 17:00:00 EEST | Business Wire | Press release
Energy Impact Partners (EIP), the global investment platform leading the transition to a sustainable energy future, has announced the formation of a European Coalition to advance new technologies and tackle climate change. EIP works closely with its investors -- more than 25 of the largest, most innovative, and environmentally conscious energy and industrial companies as well as climate-investors -- to develop cutting-edge solutions across four continents through a unique collaborative model. The EIP network collaborates by sharing insights, investing in innovative and transformative businesses, and then amplifying entrepreneurs' growth through dedicated partnerships.
“Our proven model is based on collaboration, learning, and sharing -- and it can only thrive with the right partners. We are thrilled to see some of the most innovative European players and AGL, the leading utility in Australia, join our mission as founding members.”
- Matthias Dill, CEO & Managing Director Europe for Energy Impact Partners
“Energy Impact Partners’ unique set up with strong focus in collaboration, partnerships and creating valuable insights is an efficient way to strengthen Fortum’s presence in global energy innovation ecosystem. As a partner, Fortum will gain early access to new business models and solutions in both European and US markets. The aim is to be in the frontlines in finding, piloting and scaling the innovations with potential to change the energy sector as we know it.”
- Arun Aggarwal, SVP of Fortum’s Business Technology unit
The newly formed European Coalition complements EIP’s proven North American model with investors from four continents and provide unparalleled insights for its partners and global market access for its portfolio. The coalition encompasses over 25 industrials with revenues exceeding the combined sales of Amazon, Facebook and Google and access to more than 200 million households.
“We look forward to learning, collaborating and defining the energy landscape of the future. Innovation is a global business and by collaborating we can tackle future challenges more effectively.”
- Urban Keussen, CTO of EWE and Chairman of the European Coalition
“To halt climate change, we need to make an impact now. By bringing together industry, capital and visionaries we have the best chance to succeed. We look forward to working with EIP in Norway and beyond.”
- Siri Kalvig, CEO of Nysno Climate Investments and Chair of EIP’s ESG Committee
"Climate related technologies are progressing at an impressive pace, both in Europe and globally. By partnering with EIP we get the chance to both contribute to the development and learn from the achievements of other interesting companies. The investment strengthens our position towards new energy related markets and ideas and helps us stay in the forefront in terms of smarter and more climate friendly energy solutions."
- Ståle Gjersvold, CEO at TrønderEnergi
"AGL is happy to extend our valued partnership with EIP. We have been impressed with the EIP model and we’re confident it will be successful in the European markets.”
- Simon Moorfield, Executive General Manager at AGL
About Energy Impact Partners
Energy Impact Partners (EIP) is a global investment platform leading the transition to a sustainable energy future. EIP brings together entrepreneurs and the world's most forward-looking energy and industrial companies to advance innovation. With over $1.5 billion in assets under management, EIP invests globally across venture, growth, credit and infrastructure – and has a team of more than 45 professionals based in its offices in New York, San Francisco, Palm Beach, London, Cologne and soon Oslo. For more information on EIP, please visit www.energyimpactpartners.com. EIP’s network has over 25 partners including Southern Company, Xcel Energy, Fortis, Duke Energy, Tennessee Valley Authority Asset Retirement Trust, Emera, APS, NYSNO, TronderEnergi, EWE, Enterprise Holdings, Fortum, Evergy, OG&E, Ameren, TC Energy, Alliant Energy, Avista, National Grid, PTT, TEPCO, AGL, 1898&co and MGE.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005643/en/
Contact information
EU Press
Antonella Scimemi
Burlington
antonella@burlington.cc
+44 (0)7530 815 018
U.S. Press
Tori McDonnell
Silverline Communications
tori@teamsilverline.com
01-703-338-2362
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom